April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- Remote monitoring speeds recovery, lowers complications after cancer surgery
- Common supplements may heighten bleeding risk during surgery, Polish study finds
- Keeping sensory aids in place during surgery reduces delirium risk in older hip fracture patients
- HFMA warns affordability crisis is driving up provider bad debt
- Report warns sterile processing staffing crisis threatens surgical safety
- Ascension swings to profit as outpatient push, cost cuts take hold
- High BMI alone did not raise early complication risk after outpatient TJA
- AAAHC report spotlights top accreditation deficiencies, strategies for safer ambulatory care
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement